Skip to main content
. Author manuscript; available in PMC: 2010 Apr 13.
Published in final edited form as: Cell. 2008 Nov 28;135(5):907–918. doi: 10.1016/j.cell.2008.10.025

Figure 6.

Figure 6

Increased SIRT1 activity alters tumor spectrum and increases survival of irradiated p53+/− mice. (A) Survival of irradiated p53+/− mice fed normal or resveratrol-supplemented chow (n=19 and 25, respectively). Tumor-related deaths were recorded in days after irradiation. (B) Tumor spectrum from mice in (A), legend lists dominant tumor at time of death; #no tumors detected in necropsy. (C) Western blot analysis of MACS-purified thymic CD4/CD8 double-positive (DP) T cells and splenic CD8+ T cells from MISTO mice (+ Mx-cre) and littermate controls (− Mx-cre). Mice were analyzed 14 days after Mx-cre induction; Thy: Thymus, Spl: Spleen. (D) SIRT1 mRNA expression in lymphocyte subsets from MISTO mice (closed bars) and littermate controls (open bars). BM: Bone marrow, Lin+: Lineage-positive. (E) Survival of MISTO and control p53+/− mice (n=12 and 16, respectively) in response to a single dose of 4 Gy γ-irradiation. Tumor-related deaths were recorded in days after irradiation. (F) Tumor spectrum in mice from (E), legend as in (B).